Cardiac events: Losartan beats beta blocker in patients with diabetes,HTN, & LVH


Therapy starting with the angiotensin receptor blocker (ARB) losartansignificantly reduced the risk of cardiovascular outcomes and new-onsetdiabetes compared with a beta blocker in older high-risk hypertensive patients,said Björn Dahlöf, MD. The improved outcomes with losartan occurredeven after adjusting for small differences in blood pressure reduction betweenthe two study drugs.

Related Content
© 2023 MJH Life Sciences

All rights reserved.